Alpha-lipoic acid for diabetic neuropathy: why the six-month result matters

If your feet burn or tingle, an antioxidant capsule promising relief sounds worth a look. Alpha-lipoic acid (ALA, also called thioctic acid) has been studied for diabetic neuropathy for years. Yet the answer depends on which question you ask. In a 2024 Cochrane review, the eligible six-month trial showed probably little or no difference in symptoms from placebo. Shorter studies and newer reviews still report some favorable signals. That’s not a clean yes or no, and it certainly isn’t evidence that a bottle of ALA repairs nerves.

What the six-month study actually measured

#

Cochrane looked at trials lasting at least six months, including three studies with 816 participants in its efficacy review. The clearest symptom estimate came from one trial of 330 people, not all 816: on the Total Symptom Score, the average difference at six months was -0.16 points versus placebo (95% confidence interval -0.83 to 0.51). The reviewers rated this moderate-certainty evidence and concluded ALA probably had little or no effect on symptoms over that period. Cochrane

But pain and tingling aren’t the only measurements. For lower-limb neurological impairment, the same review’s six-month estimate came from a different trial (245 people), and the reviewers rated it low certainty. They couldn’t rule out a clinically important benefit on that measure. Nor did the included studies report quality of life, foot ulcers or amputations. No result for those outcomes means no evidence of benefit in this review, not proof either way. Cochrane

That’s a distinction worth holding onto if you’ve seen a headline claiming ALA was either vindicated or debunked. The six-month symptom finding is a problem for claims of reliable, lasting relief from an oral supplement; it doesn’t test every treatment route or every shorter window.

Why the earlier results sounded more hopeful

#

Part of the appeal comes from four pooled trials of intravenous ALA. Over three weeks, that 2004 analysis reported better symptom scores than placebo. An infusion given in a study isn’t the capsule on a pharmacy shelf, though, and three weeks tells us little about what happens over months. A separate IV-then-oral trial found no clinically meaningful symptom difference at seven months. Even within the infusion story, follow-up changes the picture.

And there was a longer oral trial. In NATHAN 1, 460 people were randomized and followed for four years. Its prespecified main composite outcome missed statistical significance, though some secondary neurological-impairment measures favored ALA. A secondary signal doesn’t turn a missed main endpoint into demonstrated nerve repair (however tempting the shorthand).

ALA has a plausible antioxidant rationale, but plausibility isn’t a patient outcome. The useful question is whether a particular route improves symptoms or function for a meaningful stretch of time, not whether it sounds like it ought to. Mayo Clinic

The newer reviews don’t quite settle it either

#

Here is where the neat story comes apart. A 2025 review focused on oral ALA pooled trials and found a favorable symptom-score result, but the studies varied enormously on that outcome (I²=98%). It didn’t find a significant improvement in the lower-limb impairment score or motor nerve conduction. Its literature search ended in December 2022 - publication in 2025 doesn’t mean these were newly run trials.

A 2026 broader review also reported improvements on several symptom measures, without significant effects on HbA1c or some nerve-conduction measures. Meanwhile, an August 2026 network review combined routes and durations ranging from three to 208 weeks. Four of its nine included trials had high risk of bias, and route rankings shifted when those trials were excluded. Its lower-limb impairment network drew on just three studies. That’s thin footing for the review authors’ language about structural repair.

So why doesn’t Cochrane agree with the newer pooled symptom findings? Mostly, they’re not asking exactly the same question: the six-month eligibility rule, shorter studies, infusion versus oral treatment and different outcomes change what gets counted. Some trials recur across reviews, too; stacking reviews doesn’t create independent patients. For someone choosing an over-the-counter capsule, the short-term IV signal is especially easy to misread as a promise it can’t make. Cochrane 2025 oral review

Before you add ALA to a diabetes routine

#

Don’t let a supplement trial replace diabetes care, foot checks or treatment for neuropathic pain. The American Academy of Neurology’s patient guidance describes established medication classes to discuss for painful diabetic neuropathy; it doesn’t turn ALA into a substitute for an individualized plan. And numb feet need attention even when they don’t hurt. NIDDK advises prompt care for a new wound, redness, warmth or swelling rather than waiting to see whether a capsule helps.

Worth bringing to the appointment: your medication list, glucose readings, alcohol use and any history of thiamin (vitamin B1) deficiency. Mayo Clinic cautions that ALA could lower blood sugar and warns against its use with thiamin deficiency, a particular concern with heavy drinking. That possible glucose effect isn’t a predictable interaction in everybody - NCCIH’s 2023 summary cites a review finding no better glucose lowering than placebo. Don’t adjust insulin or other diabetes medication yourself; ask your clinician what, if anything, to monitor. Headache, heartburn, nausea and vomiting are also reported adverse effects. NCCIH

One less familiar risk deserves its own sentence. EFSA’s assessment linked supplemental ALA to rare insulin autoimmune syndrome in genetically susceptible people, which can cause serious low blood sugar; case reports can’t tell us an individual user’s absolute risk, and EFSA couldn’t establish a threshold free of that risk for susceptible people. New or unexplained low-glucose symptoms need prompt medical assessment. Severe confusion, fainting or seizures with suspected low blood sugar need emergency care. EFSA reported clinical cases

Pregnant or breastfeeding? Living with kidney disease or another significant condition? The principal neuropathy trials don’t establish a safe supplement regimen for those situations (the four-year trial excluded people with clinically significant renal disease). Get advice tailored to your situation instead of assuming the trial experience applies. US supplements aren’t preapproved by the FDA for safety or effectiveness, either. FDA

The practical bottom line

#

The best bounded six-month symptom finding is disappointing for someone hoping an oral ALA supplement will reliably ease diabetic neuropathy. But shorter and differently designed studies keep the evidence from being a universal verdict against every ALA regimen. Neither side has shown that an OTC capsule prevents ulcers or restores nerves. If you’re considering it, bring the actual goal - less pain, better function, safer feet - to your diabetes clinician. Keep the foot-care and treatment plan in place while you talk it through. Cochrane NIDDK